Diapharm has undergone a corporate restructuring. Previously separate legal entities, Diapharm Regulatory Services GmbH, Diapharm GmbH and Hälsa Pharma GmbH have now merged to form Diapharm GmbH & Co. KG.
Diapharm has obtained a THMP registration for its Urtica film-coated tablets in the United Kingdom and in Austria. The registrations can be acquired on licence by pharmaceutical companies.
SastoMed GmbH has brought a new medical device to market. Diapharm performed the certification of the Class III medical device which improves oxygen supply to chronic wounds.
Following the launch of Multiwave PRO for sample preparation applications, this extendable platform is now also available for microwave synthesis.
As part of our continuing efforts to refine our organisation and improve our offering, we have created a new position, operations manager.
INFOTEHNA’s annual pharmaceutical conference is the showpiece pharmacy event as it addresses current issues and challenges in pharmaceutical industry and provides attendees with valuable insights into solutions that will help conquer them. The conference also provides participants an opportunity to share their experiences with other professionals and experts.
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialised in protein interactions, today announces the signature of a 3-year research services agreement worth USD 2.1 million with an US multinational life sciences company.
Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialised in protein interactions, today announces the signature of an openended master agreement between its fully-owned subsidiary, Hybrigenics Services SAS, and L’Oreal.
Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialised in protein interactions, today announces that its fee-for-service scientific activities are brought to a fully-owned subsidiary named Hybrigenics Services SAS (“Société Anonyme Simplifiée”).
Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases and specialized in protein interaction services, today announces its revenues and cash position for the year ended December 31st, 2011
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.